Glycated Albumin Market - Size, Share, Trends, and Forecast

Global Glycated Albumin Market, by Product Type (Human Glycated Albumin and Animal Glycated Albumin), by Application (Diagnosis (Prediabetes, Type 1 Diabetes, and Type 2 Diabetes)) and Research), by End User (Hospitals/Clinics, Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ XX Mn in 2017 and is projected to exhibit a CAGR of XX% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1957

Increasing approval of novel glycated albumin test kits by key players in the market is expected to expand glycated albumin market size in the near future. For instance, in 2017, Japan-based Asahi Kasei Pharma Corporation received 510(k) clearance from the U. S. Food and Drug Administration (FDA) for its new Lucica Glycated Albumin-L, which is an in vitro diagnostic assay kit formulated for the U.S market.

Lucica Glycated Albumin-L is developed for the quantitative measurement of glycated albumin in human serum on compatible clinical chemistry analyzers. The approval of novel glycated albumin test kits from major regulatory bodies is expected to fuel glycated albumin kits/assays market growth over the forecast period.

Browse 35 Market Data Tables and 32 Figures spread through 190 Pages and in-depth TOC on Glycated Albumin Market, by Product Type (Human Glycated Albumin and Animal Glycated Albumin), by Application (Diagnosis (Prediabetes, Type 1 Diabetes, and Type 2 Diabetes)) and Research), by End User (Hospitals/Clinics, Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026

According to a survey conducted by the Center for Disease Control and Prevention (CDC), in 2016, over 30.3 million people in the U.S. were diagnosed with diabetes, which accounts for around 9% of the U.S. population. Such high prevalence of diabetes globally will increase the demand for glycated albumin and therefore, is expected to drive the market growth.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1957

Key Takeaways of the Glycated Albumin Market:

The global glycated market is expected to exhibit a CAGR of XX% over the forecast period (2018 – 2026), owing to increasing approval of novel glycated albumin kits by major regulatory bodies in the key regions

North America held dominant position in the global glycated albumin market and is expected to retain its dominance over the forecast period (2018 – 2026), owing to the approval of novel glycated albumin test in the region. For instance, in 2017, Asahi Kasei Pharma Corporation received the U.S. Food and Drug Administration 510(k) clearance for its Lucica Glycated Albumin-L, which is an in vitro diagnostic assay kit formulated for the U.S market.

Major players operating in the glycated albumin market include Lifespan Biosciences, Biomatik Corporation, Abbexa Ltd., G Biosciences, DRG International, Inc., Amsbio LLC, Signalway Antibody LLC, United States Biological, Diazyme Laboratories, Abnova Corporation, Maccura Biotechnology Co. Ltd., Exocell Inc., Biorbyt Ltd., and Epinex Diagnostics Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.